Biotech founder placed on leave as $400M Alzheimer's start­up idea comes un­der scruti­ny

Athi­ra Phar­ma, the Alzheimer’s biotech that emerged out of ob­scu­ri­ty last year and raised near­ly $400 mil­lion for a dark-horse ap­proach to treat­ing neu­rode­gen­er­a­tion, has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER